leisure time -WSS

leisure time

author：knowledge 2025-10-02 13:14:11 - browse：9

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Colorectal cancer study finds potential in overlooked immune cell

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

A virus, fished out of a lake, may have saved a man’s life

Bill would stop addiction treatment from triggering child abuse inquiry

3 questions for the future of Biden's cancer moonshot

Phenylephrine and the overlooked value of the placebo effect

Bristol 'take

hotspot

leisure time

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Physician executives need more than on

At least 13 dead in Texas as scorching temps continue

FDA rejects Alnylam's heart disease treatment over insufficient data

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Stroke deaths set to near 10 million globally by 2050

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA panel signals lack of confidence in Amgen cancer drug data

Tori Bowie and the unacceptable rates of Black maternal death

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

VC firm General Catalyst wants to buy a health system

Physician executives need more than on

Physician executives need more than on

Phenylephrine and the overlooked value of the placebo effect

3 questions for the future of Biden's cancer moonshot

VC firm General Catalyst wants to buy a health system

explore

hotspot

focus

leisure time